Irvine, CA, United States of America

Sinikka Virtanen


Average Co-Inventor Count = 2.0

ph-index = 4

Forward Citations = 150(Granted Patents)


Company Filing History:


Years Active: 1998-2004

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Sinikka Virtanen: Innovator in Supramolecular Therapeutics

Introduction

Sinikka Virtanen is a prominent inventor based in Irvine, CA, known for her groundbreaking work in supramolecular therapeutics. With a total of 4 patents, she has made significant contributions to the field of molecular medicine, particularly in the development of innovative therapeutic strategies.

Latest Patents

Her latest patents include a variety of advanced supramolecular structures. One notable patent describes supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids. This invention features a supramolecular component that includes effector molecules covalently joined to nucleic acids, allowing for complex interactions that can enhance therapeutic efficacy. Another patent focuses on liposomes that have attached target-binding moieties and atherosclerotic plaque-interacting moieties. This invention aims to create complexes that combine binding and therapeutic molecules to effectively target and treat conditions such as atherosclerosis.

Career Highlights

Throughout her career, Sinikka has worked with notable companies, including Burstein Laboratories and Burstein Technologies, Inc. Her innovative approaches and dedication to research have positioned her as a key figure in her field.

Collaborations

Sinikka has collaborated with various professionals, including her coworker Jorma A. Virtanen, to advance her research and develop new therapeutic solutions.

Conclusion

Sinikka Virtanen's contributions to supramolecular therapeutics highlight her role as a leading inventor in the field. Her innovative patents and collaborative efforts continue to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…